WAT

New HPLC System Launch: Waters Corporation has introduced the Alliance™ iS Bio HPLC System with integrated photodiode array detection, enhancing sensitivity by up to 80 times and improving reproducibility while reducing user errors in biopharma quality control laboratories.

Sustainability and Efficiency: The new system supports advanced spectral analysis and is designed to simplify laboratory workflows, earning sustainability recognition for its eco-friendly manufacturing practices and innovative design aimed at minimizing environmental impact.

New Product Launch: Waters Corporation has expanded its Alliance™ iS Bio HPLC product line with an integrated photodiode array (PDA) detection system, enhancing operational efficiency and sensitivity for biopharmaceutical quality control laboratories.

Performance Improvements: The new system offers significant improvements in reproducibility, reduced carryover, and decreased user errors, while also being recognized for sustainable manufacturing practices.

Stock Performance Overview: WAT's stock has a 52-week low of $279.24 and a high of $423.56, with the last trade recorded at $354.50.

Source of Information: The data regarding WAT's stock performance was sourced from Technical Analysis Channel.com.

Analyst Ratings Overview: Recent evaluations from 7 analysts on Waters Corp show a mix of bullish and bearish sentiments, with an average 12-month price target of $414.57, reflecting a positive shift from previous targets.

Financial Performance Highlights: Waters demonstrates strong financial health with a net margin of 26.51%, a return on equity of 13.49%, and prudent debt management, achieving a revenue growth rate of approximately 6.5% over the past three months.

Analyst Upgrades: Several Wall Street analysts have upgraded their ratings on various companies, including Waters Corporation, ConnectOne Bancorp, Range Resources Corporation, Global-E Online Ltd, and Ashland Inc., with corresponding increases in price targets.

Current Stock Prices: The closing stock prices for the mentioned companies are as follows: Waters Corp at $368.53, ConnectOne Bancorp at $23.73, Range Resources at $40.14, Global-E Online at $38.26, and Ashland Inc at $56.93.

Company Overview: Waters Corporation, a leading analytical instruments company with a market cap of $22.2 billion, specializes in technologies for various industries including pharmaceuticals and environmental testing, focusing on innovation and laboratory efficiency.

Stock Performance and Analyst Outlook: Despite a recent decline in stock value, WAT reported strong Q4 results exceeding expectations, with analysts giving it a "Moderate Buy" rating and a price target suggesting a potential upside of 10.1%.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Event Participation: Udit Batra, CEO of Waters Corporation, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 10:00 AM ET, with a live webcast available on their Investor Relations website.

Company Overview: Waters Corporation is a leader in analytical instruments and technologies, serving various sectors for over 65 years, ensuring safety and quality in medicines, food, and water across more than 100 countries.

Analyst Rating and Price Target: Barclays analyst Luke Sergott has maintained a Hold rating on Waters (WAT) with a price target of $400, while the overall analyst consensus is a Moderate Buy with an average price target of $410.08.

Company Performance: Waters reported a quarterly revenue of $872.71 million and a net profit of $231.4 million for the quarter ending December 31, showing growth compared to last year's revenue of $819.47 million and net profit of $216.21 million.

Company Overview and Performance: Waters Corporation, valued at $22.5 billion, specializes in analytical workflow solutions and has seen a 14.5% gain over the past year, although it underperformed compared to the S&P 500 Index's 17.6% rise. Despite challenges like foreign exchange fluctuations and inflation, the company reported strong Q4 results with an adjusted EPS of $4.10, exceeding expectations.

Analyst Ratings and Future Outlook: The consensus among 18 analysts is a "Moderate Buy" for WAT stock, with a price target of $435 from Jefferies Financial Group, indicating potential upside. Analysts expect an 8.4% growth in EPS for fiscal 2025, reflecting confidence in the company's earnings performance.

Market Growth and Investment: The global scientific instruments market is projected to grow from approximately $39.94 billion in 2024 to $62.03 billion by 2034, driven by investments in healthcare, biotechnology, and pharmaceuticals, with significant spending on R&D by top pharmaceutical companies.

Waters Corporation Performance: Waters Corporation (NYSE:WAT) is highlighted as a leading stock in the scientific instruments sector, reporting solid financials and launching innovative products, while receiving an upgrade from analysts, indicating strong potential for investment.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Analyst Ratings on Waters Corporation: Barclays analyst Luke Sergott maintains a Hold rating on Waters with a price target of $400, while TD Cowen also issued a Hold rating. In contrast, Wells Fargo has a Buy rating for the company.

Financial Performance: Waters reported a quarterly revenue of $740.31 million and a net profit of $161.5 million for the quarter ending September 28, showing an increase from the previous year’s revenue of $711.69 million and net profit of $134.55 million.

Market Performance: The S&P 500 and Dow Jones closed down, while the Nasdaq 100 saw a slight increase, driven by strong chip stock performance despite rising bond yields and unexpected inflation data that dampened rate cut expectations from the Fed.

Corporate Earnings: Mixed corporate earnings results were reported, with notable gains for CVS Health and Gilead Sciences, while companies like Waters and Biogen forecasted weaker-than-expected earnings, impacting their stock prices negatively.

Market Performance: Major US stock indexes, including the S&P 500 and Dow Jones, are down due to rising bond yields following a stronger-than-expected January consumer price index (CPI) report, which dampens expectations for interest rate cuts by the Federal Reserve.

Corporate Earnings: Mixed corporate earnings results were reported, with CVS Health and Gilead Sciences showing significant gains, while companies like Biogen and Kraft Heinz faced declines after forecasting lower-than-expected earnings.

Market Performance: Major U.S. stock indexes, including the S&P 500 and Dow Jones, are down due to rising bond yields following a stronger-than-expected January consumer price index (CPI) report, which dampens expectations for interest rate cuts by the Federal Reserve.

Corporate Earnings: Mixed corporate earnings results were reported, with notable declines for companies like Biogen and Kraft Heinz, while CVS Health and Super Micro Computer saw significant gains after exceeding earnings expectations.

Analyst Rating Update: Barclays analyst Luke Sergott has reduced the price target for Waters (WAT) from $415 to $400 while maintaining an Equal Weight rating, citing a Q1 performance that fell below expectations and a need to adjust the valuation.

Future Outlook: Despite the lowered expectations, Barclays believes there is minimal risk to management's guidance for the year and anticipates that the company will continue to perform well, leading to potential positive surprises.

Wabtec Performance: Wabtec is the worst performing S&P 500 component today, down 7.9%, but has a year-to-date gain of 1.1%.

Other Movers: Waters is also down 7.8%, while Gilead Sciences is up 8.0% on the day.

Financial Guidance for Q1 2025: Waters Corp. expects adjusted earnings between $2.17 to $2.25 per share with sales growth of 1 to 4 percent for the first quarter, while analysts anticipate earnings of $2.43 per share and sales growth of 5.76 percent.

Full-Year 2025 Projections: The company projects adjusted earnings of $12.70 to $13.00 per share with sales growth of 2.5 to 5.0 percent for fiscal 2025, compared to analyst expectations of $12.83 per share and 5.23 percent sales growth.